{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "697148dd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Google API Key loaded successfully.\n",
      "Loading existing vector store from disk...\n",
      "Vector store loaded successfully!\n",
      "\n",
      "--- Testing the AI Assistant ---\n",
      "\n",
      "Question 1: What are the primary challenges in diagnosing MASH, and how do non-invasive tests (NITs) like the FIB-4 score address these challenges?\n",
      "Answer 1: The primary challenges in diagnosing MASH are:  1) its silent nature, leading to a high percentage (90%) of undiagnosed cases even in at-risk individuals; 2) low medical familiarity with diagnostic methods like FIB-4 and hepatic elastography, resulting in underutilization of non-invasive testing options; 3) a lack of widely disseminated clinical guidelines for screening and management, creating uncertainty among healthcare professionals about when and how to investigate; and 4) structural and access barriers hindering testing.\n",
      "\n",
      "Non-invasive tests (NITs) such as the FIB-4 score directly address these challenges.  The FIB-4 score, a first-line NIT, is simple to calculate using readily available patient data (age and common blood tests), making it easily accessible in primary care settings.  This increased accessibility helps overcome the lack of familiarity with diagnostic methods and the lack of widely disseminated guidelines by providing a straightforward initial screening tool.  A high FIB-4 score (≥1.3, or ≥2.0 for those ≥65 years) then flags patients for further assessment with second-line NITs like transient elastography (FibroScan and Velacur), which are also non-invasive and can be performed in clinics or radiology departments.  These second-line NITs provide more detailed information about liver fibrosis, allowing for earlier and more accurate diagnosis and risk stratification, thus mitigating the problem of late diagnosis due to MASH's silent nature.  While the context doesn't detail how NITs address structural and access barriers directly, their ease of use and availability in various settings suggests a potential reduction in these barriers.\n",
      "\n",
      "Question 2: According to the provided Brazilian guidelines, what is the recommended screening and follow-up protocol for MASLD in overweight or obese individuals?\n",
      "Answer 2: The Brazilian guidelines recommend screening for MASLD in adult individuals with a BMI > 23 kg/m² for those of Asian origin,  in accordance with World Health Organization recommendations.  Abdominal ultrasonography is recommended as the initial screening method for hepatic steatosis in overweight/obese patients.  The guidelines also include recommendations for follow-up, nonpharmacologic treatment, and pharmacologic and surgical treatment, though the specifics of these are not detailed in the provided text.\n",
      "\n",
      "Question 3: What is the global prevalence of MASH, and how does it differ in Latin America compared to the rest of the world?\n",
      "Answer 3: The global prevalence of MASH is estimated to be 3% to 5%, with the most recent guidelines estimating it to be 5.27% (5%–7%).  In Latin America, the prevalence is 7.1%, exceeding the global average.  It is estimated that approximately 32 million people in Latin America live with MASH.\n",
      "\n",
      "Question 4: What lifestyle modifications are recommended for the management of MASLD, and what is the evidence for their effectiveness?\n",
      "Answer 4: Lifestyle modifications recommended for the management of MASLD include a healthy diet, increased physical activity, and decreased weight.  The text states that weight loss goals vary depending on the patient's weight status (3-5% for overweight/obese, prevention of further weight gain for normal weight).  However, the evidence for effectiveness is limited.  While a weight reduction of >10% is desirable to improve fibrosis, a limited proportion of individuals achieve even a 5% reduction. Long-term adherence to behavioral changes is often insufficient, and data on long-term dietary interventions are limited, with studies ranging from 2-24 months.  Studies with 12-24 month follow-ups show maximal weight loss at 6 months followed by gradual regain, resulting in a net weight loss of about 5% at 12-24 months and partial regain of liver lipid.\n",
      "\n",
      "Question 5: What are the key recommendations for the pharmacological treatment of MASH, including the use of resmetirom?\n",
      "Answer 5: Key recommendations for pharmacological treatment of MASH, based on the provided text, include:\n",
      "\n",
      "* **Resmetirom:**  If approved locally, resmetirom may be considered for non-cirrhotic individuals with MASLD and either advanced fibrosis, at-risk steatohepatitis with significant fibrosis (confirmed by biopsy or validated non-invasive panels), or risk of adverse liver-related outcomes (defined by elastography or biomarkers).  Treatment should be stopped if MASH worsens; continued treatment can be considered on an individual basis for those with partial improvement or stability.  Long-term efficacy and safety monitoring in real-world clinical registries is suggested.\n",
      "\n",
      "* **No MASH-targeted pharmacotherapy** is currently recommended for adults with MASH at the cirrhotic stage.\n",
      "\n",
      "* **Vitamin E** is not recommended as a MASH-targeted therapy due to the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis from large phase III trials and potential long-term risks.\n",
      "\n",
      "* **Future MASH therapies:**  Thorough assessment of  diometabolic comorbidities, efficacy of MASH-targeting therapies (focusing on liver-related outcomes), non-response and stopping rules, long-term metabolic, cardiovascular, and oncological safety, and potential additive or synergistic effects of combination therapies are needed.  All agents receiving accelerated approval must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, HCC) in extended phase III trials and real-world settings.  Treatment decisions should also consider LSM improvement, coverage restrictions, safety concerns, side effects, patient preference, and potential worsening of liver disease.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# --- STEP ZERO: NETWORK CONFIGURATION FOR WSL ---\n",
    "import os\n",
    "os.environ[\"GRPC_DNS_RESOLVER\"] = \"native\"\n",
    "# --- END OF NETWORK CONFIGURATION ---\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import time\n",
    "import langchain\n",
    "\n",
    "# Load environment variables from the .env file\n",
    "load_dotenv()\n",
    "\n",
    "# Check if the Google API key was loaded\n",
    "if 'GOOGLE_API_KEY' not in os.environ:\n",
    "    print(\"Error: Google API Key not found. Check your .env file.\")\n",
    "else:\n",
    "    print(\"Google API Key loaded successfully.\")\n",
    "\n",
    "# --- Imports for AI libraries ---\n",
    "from langchain_community.document_loaders import DirectoryLoader, PyPDFLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_huggingface import HuggingFaceEmbeddings\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain_google_genai import GoogleGenerativeAI\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.prompts import PromptTemplate\n",
    "\n",
    "# --- STEP 3.3.3: CREATE OR LOAD THE VECTOR STORE ---\n",
    "# Define the path for the saved FAISS index\n",
    "FAISS_INDEX_PATH = \"faiss_index\"\n",
    "\n",
    "# Define the embedding model to be used.\n",
    "model_name = \"sentence-transformers/all-MiniLM-L6-v2\"\n",
    "model_kwargs = {'device': 'cpu'} # Use 'cuda' if you have a configured GPU\n",
    "encode_kwargs = {'normalize_embeddings': False}\n",
    "embeddings = HuggingFaceEmbeddings(\n",
    "    model_name=model_name,\n",
    "    model_kwargs=model_kwargs,\n",
    "    encode_kwargs=encode_kwargs\n",
    ")\n",
    "\n",
    "# Check if the vector store already exists\n",
    "if os.path.exists(FAISS_INDEX_PATH):\n",
    "    print(\"Loading existing vector store from disk...\")\n",
    "    # allow_dangerous_deserialization is needed for loading local FAISS indexes\n",
    "    vectorstore = FAISS.load_local(FAISS_INDEX_PATH, embeddings, allow_dangerous_deserialization=True)\n",
    "    print(\"Vector store loaded successfully!\")\n",
    "else:\n",
    "    print(\"No existing vector store found. Creating a new one...\")\n",
    "    # --- STEP 3.3.1: LOAD THE KNOWLEDGE BASE ---\n",
    "    loader = DirectoryLoader('./knowledge_base/', glob=\"./*.pdf\", loader_cls=PyPDFLoader)\n",
    "    documents = loader.load()\n",
    "    print(f\"Total documents loaded: {len(documents)}\")\n",
    "\n",
    "    # --- STEP 3.3.2: SPLIT DOCUMENTS INTO CHUNKS ---\n",
    "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=150)\n",
    "    texts = text_splitter.split_documents(documents)\n",
    "    print(f\"Total text chunks created: {len(texts)}\")\n",
    "\n",
    "    # Create the FAISS vector store from the text chunks and the embedding model.\n",
    "    print(\"\\nCreating embeddings and vector store... This might take a moment.\")\n",
    "    vectorstore = FAISS.from_documents(texts, embeddings)\n",
    "    print(\"Vector store created successfully!\")\n",
    "\n",
    "    # Save the vector store to disk for future use\n",
    "    vectorstore.save_local(FAISS_INDEX_PATH)\n",
    "    print(f\"Vector store saved to disk at: {FAISS_INDEX_PATH}\")\n",
    "\n",
    "\n",
    "# --- STEP 3.3.4: CONFIGURE THE LLM AND THE RETRIEVAL CHAIN ---\n",
    "# Configure the LLM that will be used to generate answers\n",
    "llm = GoogleGenerativeAI(model=\"gemini-1.5-flash\", temperature=0.3) # <--- FINAL CORRECTED MODEL NAME\n",
    "\n",
    "# Create a prompt template to instruct the LLM on how to behave\n",
    "prompt_template = \"\"\"\n",
    "Use the following context to answer the question in a detailed and precise manner.\n",
    "If the answer is not in the context, say \"The information is not available in my knowledge base.\"\n",
    "\n",
    "Context:\n",
    "{context}\n",
    "\n",
    "Question:\n",
    "{question}\n",
    "\n",
    "Answer:\n",
    "\"\"\"\n",
    "PROMPT = PromptTemplate(template=prompt_template, input_variables=[\"context\", \"question\"])\n",
    "\n",
    "# Create the Retrieval Question-Answering chain\n",
    "qa_chain = RetrievalQA.from_chain_type(\n",
    "    llm=llm,\n",
    "    chain_type=\"stuff\",\n",
    "    retriever=vectorstore.as_retriever(search_kwargs={\"k\": 3}), # Retrieve the 3 most relevant chunks\n",
    "    return_source_documents=True,\n",
    "    chain_type_kwargs={\"prompt\": PROMPT}\n",
    ")\n",
    "\n",
    "# --- STEP 3.3.5: TESTING THE SYSTEM ---\n",
    "print(\"\\n--- Testing the AI Assistant ---\")\n",
    "\n",
    "# Now you can ask questions directly without debug mode for a cleaner output\n",
    "question1 = \"What are the primary challenges in diagnosing MASH, and how do non-invasive tests (NITs) like the FIB-4 score address these challenges?\"\n",
    "print(f\"\\nQuestion 1: {question1}\")\n",
    "response1 = qa_chain.invoke({\"query\": question1})\n",
    "print(f\"Answer 1: {response1['result']}\\n\")\n",
    "\n",
    "question2 = \"According to the provided Brazilian guidelines, what is the recommended screening and follow-up protocol for MASLD in overweight or obese individuals?\"\n",
    "print(f\"Question 2: {question2}\")\n",
    "response2 = qa_chain.invoke({\"query\": question2})\n",
    "print(f\"Answer 2: {response2['result']}\\n\")\n",
    "\n",
    "question3 = \"What is the global prevalence of MASH, and how does it differ in Latin America compared to the rest of the world?\"\n",
    "print(f\"Question 3: {question3}\")\n",
    "response3 = qa_chain.invoke({\"query\": question3})\n",
    "print(f\"Answer 3: {response3['result']}\\n\")\n",
    "\n",
    "question4 = \"What lifestyle modifications are recommended for the management of MASLD, and what is the evidence for their effectiveness?\"\n",
    "print(f\"Question 4: {question4}\")\n",
    "response4 = qa_chain.invoke({\"query\": question4})\n",
    "print(f\"Answer 4: {response4['result']}\\n\")\n",
    "\n",
    "question5 = \"What are the key recommendations for the pharmacological treatment of MASH, including the use of resmetirom?\"\n",
    "print(f\"Question 5: {question5}\")\n",
    "response5 = qa_chain.invoke({\"query\": question5})\n",
    "print(f\"Answer 5: {response5['result']}\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "06b44160-954f-4e9f-b5c8-3f4a18b4cc62",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
